País: Regne Unit
Idioma: anglès
Font: MHRA (Medicines & Healthcare Products Regulatory Agency)
Orion Pharma (UK) Ltd
G03FB06
Not applicable
No Controlled Drug Status
Never Valid To Prescribe As A VMP
BNF: 06040101; GTIN: 6432100003256
PACKAGE LEAFLET: INFORMATION FOR THE USER TRIDESTRA® Estradiol valerate and Medroxyprogesterone acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET: 1. What Tridestra is and what it is used for 2. What you need to know before you take Tridestra 3. How to take Tridestra 4. Possible side effects 5. How to store Tridestra 6. Contents of the pack and other information 1. WHAT TRIDESTRA IS AND WHAT IT IS USED FOR Tridestra is a Hormone Replacement Therapy (HRT). It contains two types of female hormones, an oestrogen and a progestogen. Tridestra is used for: RELIEF OF MENOPAUSAL SYMPTOMS During the menopause, the amount of the oestrogen produced by a woman’s body drops. This can cause symptoms such as hot face, neck and chest ("hot flushes"). Tridestra alleviates these symptoms. You will only be prescribed Tridestra if your symptoms seriously hinder your daily life. PREVENTION OF OSTEOPOROSIS After the menopause some women may develop fragile bones (osteoporosis). You should discuss all available options with your doctor. If you are at an increased risk of fractures due to osteoporosis and other medicines are not suitable for you, you can use Tridestra to prevent osteoporosis after menopause. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TRIDESTRA MEDICAL HISTORY AND REGULAR CHECK-UPS The use of HRT carries risks which need to be considered when deciding whether to start taking it, or whether to carry on taking it. The experience in treating women with a premature menopause (due to ovarian failure or surger Llegiu el document complet
OBJECT 1 Tridestra Tablets Summary of Product Characteristics Updated 02-Feb-2022 | Orion Pharma (UK) Limited • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Tridestra 2. Qualitative and quantitative composition Tridestra tablet (white): Estradiol valerate 2 mg Excipient with known effect 82 mg lactose (as monohydrate). Tridestra tablet (light blue, sometimes spotted): Estradiol valerate 2 mg Medroxyprogesterone acetate 20 mg Excipient with known effect 143 mg lactose (as monohydrate). Tridestra tablet (yellow): Placebo Excipient with known effect 82 mg lactose (as monohydrate). For the full list of excipients, see section 6.1 3. Pharmaceutical form Tablets, oral. 4. Clinical particulars 4.1 Therapeutic indications Tridestra is indicated in adult women for: i) Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in peri- and post-menopausal women. ii) Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, Llegiu el document complet